Vorapaxar: A novel protease-activated receptor-1 inhibitor

Expert Opinion on Investigational Drugs

Volumn 20, Issue 10, 2011, Pages 1445-1453

  Gurbel, Paul A ^a   Jeong, Young Hoon ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

PAR 1 receptor; Platelet; Thrombosis; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CLOPIDOGREL; KETOCONAZOLE; PEPDUCIN; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 INHIBITOR; RIFAMPICIN; SCH 205831; SCH 602539; THROMBIN; TICAGRELOR; UNCLASSIFIED DRUG; VORAPAXAR;

BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD; FOOD DRUG INTERACTION; HEART INFARCTION; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; MONOTHERAPY; NONHUMAN; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LACTONES; MALE; MOLECULAR TARGETED THERAPY; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1;

EID: 80052751010     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.606809     Document Type: Review

References (46)

1. World Health Organization. Atlas of heart disease and stroke. World Health Organization; Geneva: 2004
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94.
3. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004;2:535-45 (Pubitemid 39069789)
4. Tantry US, Etherington A, Bliden KP, Gurbel PA. Antiplatelet therapy: current strategies and future trends. Future Cardiol 2006;2:343-66
5. Brass LF. Thrombin and platelet activation. Chest 2003;124:18S-25S (Pubitemid 37128432)
6. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
7. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
8. Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 2009;5:989-1004
9. Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010;121:569-83.
10. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009;102:248-57
11. Chintala M, Shimizu K, Ogawa M, et al. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 2008;108:433-8
12. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64
13. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998;394:690-4 (Pubitemid 28389797)
14. Leger AJ, Jacques SL, Badar J, et al. A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006;113:1244-54
15. De Candia E, Hall SW, Rutella S, et al. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001;276:4692-8
16. Voss B, McLaughlin JN, Holinstat M, et al. PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Mol Pharmacol 2007;71:1399-406 (Pubitemid 46658692)
17. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51:3061-4 (Pubitemid 351821864)
18. Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Atheroscler Thromb Vasc Biol 2008;28:e32-e149
19. Gurbel PA, Bliden KP, Saucedo JF, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol 2009;53:648-57
20. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006;114:1070-7. (Pubitemid 44358884)
21. Takada M, Tanaka H, Yamada T, et al. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res 1998;82:980-7 (Pubitemid 28225938)
22. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003;304:855-61 (Pubitemid 36152366)
23. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol 1993;22:609-16 (Pubitemid 23286758)
24. Kato Y, Kita Y, Hirasawa-Taniyama Y, et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 2003;473:163-9 (Pubitemid 36929880)
25. Nelken NA, Soifer SJ, O'Keefe J, et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992;90:1614-21
26. Maeda NY, Carvalho JH, Otake AH, et al. Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thromb Res 2010;125:38-43
27. McNamara CA, Sarembock IJ, Bachhuber BG, et al. Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin Thromb Hemost 1996;22:139-44 (Pubitemid 26239906)
28. Gurbel PA, Zaman K, Bliden KP, Tantry U. Maximum clot strength is a novel and highly predective indicator of restenosis; A potential future measure to determine who needs antiproliferative therapy and how much. J Am Coll Cardiol 2006;47:43B
29. Kogushi M, Kobayashi H, Matsuoka T, et al. Antithrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs [abstract]. Circulation 2003;108(Suppl IV):280
30. Chintala M, Ahn HS, Foster C, et al. Antithrombotic effects of SCH 205831: a potent, selective and orally active antagonist of the PAR-1 thrombin receptor. J Thromb Haemost 2005;3(Suppl 1):OR286
31. Chintala M, Strony J, Yang B, et al. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2010;30:2143-9
32. Kosoglou T, Reyderman L, Fales RR, et al. Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor (PAR-1) antagonist SCH 530348 [abstract]. Circulation 2005;112(Suppl II):II-32
33. Chackalamannil S, Wang Y, Greenlee WJ, et al.Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51(11):3061-4. (Pubitemid 351821864)
34. Chintala M, Ahn HS, Foster C, et al.Pharmacologic profile of SCH 530348, a novel oral antiplatelet agent selective for the protease-activated receptor-1 (PAR-1). Am Heart Assoc Sci Sessions 2008;118(18):abstract 1710
35. Chintala M, Vemulapalli S, Kurowski S, et al.SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2008;28(6):abstract P579
36. Reyderman L, Kosoglou T, Tseng J, et al.The effect of food and antacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects. Clin Pharmacol Ther 2009;85(Suppl 1):abstract PI-42
37. TRA*CER Executive and Steering Committees. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: study design and rationale. Am Heart J 2009;158:327-34.e4
38. Kosoglou T, Reyderman L, Kasserra C, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clin Pharmacol Ther 2008;83(Suppl 1):S55
39. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;373:919-28
40. Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010;17:156-64
41. Shinohara Y, Goto S, Doi M, et al. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis 2010; Oct 13. [Epub ahead of print]
42. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009;158:335-41.e3
43. Trial to assess the ocular safety of SCH 530348 in patients with atherosclerosis (Study P05183AM1). Available from: http://www.clinicaltrials. gov/ct2/show/NCT00617123? term=SCH530348&rank=5 [Accessed on 19 January 2011]
44. MERCK press release. Available from: http://www.merck.com/newsroom/ newsrelease-archive/research-and-development/2011-0119.html [Accessed on 24 January 2011]
45. O'Donoghue ML, Bhatt DL, Wiviott SD, et al. on behalf of the LANCELOT-ACS Investigators. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 2011;123:1843-53
46. Wiviott SD, Flather MD, O'Donoghue ML, et al. on behalf of the LANCELOT-CAD Investigators. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation 2011;123:1854-63